SCHEMBL129862

SCHEMBL129862

CCOc1ccc(-c2nn(C)c3ncnc(N)c23)cc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 15/20 0.80
ABL1 P00519 11/20 0.80
PIK3CD O00329 10/20 0.80
PIK3CA P42336 10/20 0.80
PIK3CB P42338 10/20 0.80
PIK3CG P48736 10/20 0.80
PRKDC P78527 10/20 0.80
HCK P08631 9/20 0.80
EGFR P00533 9/20 0.80
MTOR P42345 8/20 0.80
EPHB4 P54760 8/20 0.80
KDR P35968 7/20 0.80
NUDT14 O95848 1/20 0.71
NUDT5 Q9UKK9 1/20 0.71
LCK P06239 3/20 0.57
CSK P41240 3/20 0.57
EPHA3 P29320 1/20 0.57
PI4KB Q9UBF8 3/20 0.57
KCNH2 Q12809 1/20 0.55
FGFR1 P11362 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12608279 0.89 SRC (1.00) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL130752 0.86 NUDT14 (0.74) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL129870 0.85 SRC (0.77) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL23917529 0.85 PIK3CD (0.67) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL130425 0.84 PIK3CD (1.00) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL30782445 0.83 NUDT14 (0.69) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL12366 0.83 NUDT14 (0.69) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL130529 0.83 NUDT14 (1.00) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL130644 0.83 NUDT14 (0.70) SRCABL1PIK3CDPIK3CAPIK3CB
SCHEMBL130643 0.82 NUDT14 (0.68) SRCABL1PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2021-12-30 US disclosed
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2021-06-01 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2019-10-15 US disclosed
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2019-09-19 US disclosed
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2018-04-26 US disclosed
US-9775841-B2 Compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2017-10-03 US disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 US disclosed
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS AG (CH) 2015-11-12 US disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES RHIZEN PHARMACEUTICALS SA (CH) 2012-11-15 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10442783-B2 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases PIK3CB, PIK3CD, PDPK1 SRC 202/4885ABL1 329/4885PIK3CD 2/4885
US-20210401840-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885PIK3CD 47/4885
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885PIK3CD 70/4885
US-11020399-B2 Intermediates useful in the synthesis of compounds as modulators of protein kinases MAP4K2, MAP3K20, MAP3K1 SRC 85/4885ABL1 106/4885PIK3CD 288/4885
US-20150320752-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885PIK3CD 47/4885
US-20120289496-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885PIK3CD 47/4885
US-20180110783-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885PIK3CD 47/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885PIK3CD 70/4885
US-20190282581-A1 NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES PRKCA, PRKCH, PRKCB SRC 285/4885ABL1 334/4885PIK3CD 47/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885PIK3CD 70/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885PIK3CD 70/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A SRC 110/4885ABL1 258/4885PIK3CD 103/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885PIK3CD 70/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885ABL1 465/4885PIK3CD 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.